Latest Targeted therapy Stories
ION Solutions, a diversified physician services organization whose membership represents more than half of the private practice oncologists in the United States, today announced the selection
Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912.
DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5s2nhx/drug_delivery_in) has announced the addition a new report
PhenoPath is one of the first labs in the US to adopt all the complex changes of the 2013 ASCO-CAP HER2 Testing Guideline updates in breast cancer. Seattle,
Molecularly-Guided Therapies of Critical Importance for Rare Cancers with Fewer Treatment Options IRVING, Texas, Jan.
Research uncovers clinically actionable biomarker targets and key treatment insights for colorectal, gastric, neuroendocrine and appendiceal cancer patients IRVING, Texas, Jan.
Five Distinguished Researchers Receive First-Time Grant WHITE PLAINS, N.Y., Jan.
Trial Will Compare Investigational Compound's Efficacy and Safety as an Addition to Standard Treatment NORTH CHICAGO, Ill., Jan.
To Expand Clinical Trial for Advanced Ovarian Clear Cell Carcinoma ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- EntreMed, Inc.
University of Cincinnati (UC) Cancer Institute researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most effective treatment strategy for patients with the condition.
- Having no light.
- Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.